Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44511/1/10555_2004_Article_203064.pd
Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains...
Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunothera...
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few thera...
ContextAfter initiation of androgen deprivation therapy (ADT), most patients progress to castration-...
Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progressi...
Prostate cancer is the second most common male malignancy in the western world an increasing inciden...
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches tha...
<p><em>Mechanisms of development of hormone refractory prostate cancer currently not fully understoo...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches tha...
Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients prog...
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate ca...
Fionnuala Crowley,1 Michelle Sterpi,1 Conor Buckley,1 Lauren Margetich,1 Shivani Handa,1 Zach Dovey2...
Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in managing c...
In recent years, many therapeutic advances have been made in the management of castration-resistant ...
Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains...
Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunothera...
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few thera...
ContextAfter initiation of androgen deprivation therapy (ADT), most patients progress to castration-...
Prostate cancer relies on signaling through the androgen receptor (AR) for maintenance and progressi...
Prostate cancer is the second most common male malignancy in the western world an increasing inciden...
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches tha...
<p><em>Mechanisms of development of hormone refractory prostate cancer currently not fully understoo...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches tha...
Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all patients prog...
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate ca...
Fionnuala Crowley,1 Michelle Sterpi,1 Conor Buckley,1 Lauren Margetich,1 Shivani Handa,1 Zach Dovey2...
Prostate cancer is the second leading cause of cancer deaths in the USA. The challenge in managing c...
In recent years, many therapeutic advances have been made in the management of castration-resistant ...
Despite advances in prostate cancer diagnosis and management, morbidity from prostate cancer remains...
Novel Agents for Castrate-Resistant Prostate Cancer Include Potent Androgen Blockers and Immunothera...
Purpose: Hormone resistance remains a significant clinical problem in prostate cancer with few thera...
DOI
Add to ORKG